TMCnet News
OpGen to Present Advancements in Antibiotic Susceptibility and Whole Genome Sequencing at ASM Microbe 2017GAITHERSBURG, Md., May 25, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that data on its Acuitas® Rapid Test in development and Acuitas Whole Genome Sequence Analysis will be presented at ASM Microbe 2017 being held June 1-5, 2017 in New Orleans, LA. These data will demonstrate the company’s ability to predict phenotypic resistance across antibiotic classes for Gram-negative infections using rapid genetic testing and predictive algorithms from its Acuitas Lighthouse® Knowledgebase. It will also showcase advances in being able to discriminate bacterial strains using more genes to solve current limitations with conventional strain typing methods. The details for the poster presentations at ASM Microbe are as follows: Session info: 186 - AAID01 - Antibacterial Resistance: Genomics and New Methodologies to Trace Antimicrobial Resistance Date and time: Saturday, June 3, 12:15 – 2:15 PM CEDT Location: Exhibit Hall D, Exhibit and Poster Hall Session info: 186 - AAID01 - Antibacterial Resistance: Genomics and New Methodologies to Trace Antimicrobial Resistance About OpGen OpGen®, Acuitas®, Acuitas Lighthouse® and QuickFISH® are registered trademarks of OpGen, Inc. OpGen Contact: Michael Farmer Director, Marketing 240-813-1284 [email protected] [email protected] Investor and Media Contact: Cammy Duong MacDougall Biomedical Communications 781-591-3443 [email protected] |